In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth

Cancer Science

Volumn 101, Issue 9, 2010, Pages 1955-1964

  Hamaguchi, Naohiko ^a   Hamada, Hironobu ^a   Miyoshi, Seigo ^a   Irifune, Kazunori ^a   Ito, Ryoji ^a   Miyazaki, Tatsuhiko ^a   Higaki, Jitsuo ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; TROGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL GROWTH; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MALE; MOUSE; NONHUMAN; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; THORAX TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMANS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FLOW CYTOMETRY; G1 PHASE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MESOTHELIOMA; MICE; MICE, SCID; PLEURAL NEOPLASMS; PPAR GAMMA; THIAZOLIDINEDIONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955941433     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01632.x     Document Type: Article

References (33)

1. Pistolesi M, Rusthoven J. Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies. Chest 2004, 126:1318-29.
2. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009, 27:2081-90.
3. Berghmans T, Paesmans M, Lalami Y. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002, 38:111-21.
4. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347:645-50.
5. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome roliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995, 270:12953-6.
6. Koeffler HP. Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res 2003, 9:1-9.
7. Tontonoz P, Singer S, Forman BM. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA 1997, 94:237-41.
8. Sarraf P, Mueller E, Jones D. Differentiation and reversal of malignant changes in colon cancer through PPAR gamma. Nat Med 1998, 4:1046-52.
9. Mueller E, Sarraf P, Tontonoz P. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998, 1:465-70.
10. Elstner E, Müller C, Koshizuka K. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998, 95:8806-11.
11. Yu J, Qiao L, Zimmermann L. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 2006, 43:134-43.
12. Chaffer CL, Thomas DM, Thompson EW, Williams ED. PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 2006, http://dx.doi.org/10.1186/1471-2407-6-53, doi 10.1186/1471-2407-6-53
13. Shiau CW, Yang CC, Kulp SK. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Res 2005, 65:1561-9.
14. Yokoyama A, Kohno N, Fujino S. Origin of heterogeneity of interleukin-6 (IL-6) levels in malignant pleural effusions. Oncol Rep 1994, 1:507-11.
15. Nakataki E, Yano S, Matsumori Y. Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor. Cancer Sci 2006, 97:183-91.
16. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
17. Reddy RC, Srirangam A, Reddy K. Chemotherapeutic drugs induce PPAR-gamma expression and show sequence-specific synergy with PPAR-gamma ligands in inhibition of non-small cell lung cancer. Neoplasia 2008, 10:597-603.
18. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998, 338:916-7.
19. Gale EA. Lessons from the glitazones: a story of drug development. Lancet 2001, 357:1870-5.
20. Graham DJ, Green L, Senior JR, Nourjah P. Troglitazone-induced liver failure: a case study. Am J Med 2003, 114:299-306.
21. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 2004, 5:419-29.
22. Han S, Sidell N, Fisher PB, Roman J. Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells. Clin Cancer Res 2004, 10:1911-9.
23. Koga H, Harada M, Ohtsubo M. Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells. Hepatology 2003, 37:1086-96.
24. Li Q, Yano S, Ogino H. The therapeutic efficacy of anti-vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Clin Cancer Res 2007, 13:5918-25.
25. Sorenson CM, Eastman A. Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res 1988, 48:6703-7.
26. Sorenson CM, Barry MA, Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 1990, 82:749-55.
27. Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 2001, 59:657-63.
28. DiPaola RS. To arrest or not to G(2)-M Cell-cycle arrest: commentary re: A. K. Tyagi et al., Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G(2)-M arrest, and apoptosis. Clin Cancer Res 2002, 8:3311-4.
29. Kulke MH, Demetri GD, Sharpless NE. A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 2002, 8:395-9.
30. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP. Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat 2003, 79:391-7.
31. Girnun GD, Naseri E, Vafai SB. Synergy between PPARgamma ligands and platinum-based drugs in cancer. Cancer Cell 2007, 11:395-406.
32. Tikoo K, Kumar P, Gupta J. Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats. BMC Cancer 2009, 9:107.
33. Copland JA, Marlow LA, Kurakata S. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene 2006, 25:2304-17.